NVCT · Nuvectis Pharma

The thesis

Nuvectis Pharma's shares are more likely to lag the S&P 500 over the next three months. The value rests on turning two licensed Haisco drugs, NXP100 (ciprocopan) and NXP200, into US development programs, and the company's guided US investigational new drug (IND) submissions for both by year-end 2026 are what settle it. Positive NXP200 data are already out, so the remaining catalysts are filings rather than new results.

The NXP200 data came on 26 October 2026 at the European Society for Medical Oncology congress. Nuvectis reported an objective response rate of 40.0% (8 of 20 patients, including 3 complete responses) in BRAF V600-mutated high-grade glioma, and 42.9% (3 of 7) in low-grade glioma. Haisco ran the study in China.

The third-quarter report on 4 November 2026 extended the cash runway into the second half of 2029, according to a Finsee review of the filing. It also moved the NXP900 lung cancer data update from the fourth quarter of 2026 to the first half of 2027. The shares closed at $17.76 on 5 November 2026, the session after the report, and at $20.91 on 6 November 2026.

The last close was $20.23 on 12 November 2026. That is 30.9% below the 52-week intraday high of $29.27 set on 29 June 2026, and the 3-month price change is 6.7%. The published kill line has not been crossed.

Bullish and bearish views on Nuvectis Pharma, Inc.

The bull case on Nuvectis Pharma, Inc. (NVCT), in brief: NXP200 data show durable responses. The bear case: the market gave the data little credit.

Bull case

• NXP200 data show durable responses. In high-grade glioma, median duration of response was 6.97 months and median overall survival 17.15 months, per BiopharmaWatch's summary of the 26 October 2026 release. Tumor reduction occurred in 22 of 27 patients, per the same summary.
• Cash runway lengthened. Finsee's review of the 4 November 2026 report shows $140.7 million of cash at 30 September 2026, up from $22.2 million the quarter before, with runway into the second half of 2029.
• US IND guidance is intact. Finsee's review of the third-quarter report shows year-end 2026 IND submissions still planned for both NXP100 and NXP200. The company also expects an FDA update on the NXP100 regulatory path in paroxysmal nocturnal hemoglobinuria (PNH).
• Regulatory marker in China. China granted NXP200 breakthrough therapy designation in BRAF V600-mutant high-grade glioma on 24 September 2026.
• Shares hold above the long-term trend. The last close of $20.23 on 12 November 2026 sits above the 200-day average of $15.12, per adjusted daily closes.

Bear case

• The market gave the data little credit. The shares closed between $20.91 and $21.08 on the four sessions from 6 November to 11 November 2026, then at $20.23 on 12 November 2026. The 52-week high remains $29.27.
• Shares sit below the 50-day average. The 12 November 2026 close of $20.23 is under the 50-day average of $20.69, per adjusted daily closes.
• NXP900 slipped again. Finsee's review of the 4 November 2026 report says the Phase 1b lung cancer data update moved from the fourth quarter of 2026 to the first half of 2027.
• Quarterly loss widened. Nuvectis reported a third-quarter loss of $1.02 per share against a $0.24 estimate, per a 4 November 2026 earnings headline. Finsee attributes the $30.1 million net loss mainly to a $20.0 million upfront fee to Haisco.
• The share count keeps rising. Finsee reports 35.0 million common shares outstanding at 30 September 2026, up 31.2% in the quarter. A Form S-3 registration statement on file allows further sales without a new registration.
• Study design limits comparisons. The NXP200 study is small, uncontrolled and run in China. The 40.0% high-grade response rate rests on 20 patients, and Nuvectis's rights exclude Greater China, so the China data create no revenue for it.

Price setup

The last close was $20.23 on 12 November 2026. The 50-day average is $20.69 and the 200-day average is $15.12, both as of that close. The shares have sat just under the 50-day average after closing at $21.08 on 10 November 2026.

The 52-week closing low was $5.81 on 2 December 2025, and the 52-week intraday high was $29.27 on 29 June 2026. The market has priced in the NXP200 data and the longer runway: the close of $17.76 on 5 November 2026 recovered to above $20 within one session and has held there.

Nuvectis has 35.0 million shares outstanding, so single headlines can move the price. The company has issued stock into prior strength. No earnings report falls before the 31 December 2026 filing deadline; the 10-Q was filed on 4 November 2026.

Catalysts ahead

• ~31 December 2026 (est.): Guided year-end deadline for US IND submissions for NXP100 and NXP200, plus an FDA update on the NXP100 path in PNH. Announced submissions for both drugs are the execution condition of the thesis.
• ~31 March 2027 (est.): Further China Phase 1b NXP200 updates, including other tumor types, guided for early 2027. Shows whether the glioma responses extend to other BRAF-mutated tumors.
• ~30 June 2027 (est.): End of the first half of 2027, the revised window for the NXP900 plus lorlatinib lung cancer data update. The update has already moved from the fourth quarter of 2026; another slip would weaken confidence in company timetables.

What would change the view

A daily close above $25.89, well over the $20.91–$21.08 closes of 6 November to 11 November 2026, which would show the shares leading the S&P 500. FDA clearance of a US IND for NXP100 or NXP200 would also show the shares leading.

What it trades with

NVCT trades on its own clinical news and filings, not with an index or a peer group. Funding conditions for small-cap biotech, often tracked by the SPDR S&P Biotech ETF (XBI), affect what investors pay for pre-revenue stories. Haisco's China programs are the source of the NXP200 data, so Haisco disclosures can move the shares. This is a single-name view with no peer comparison drawn.